hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06364813 id: H20-01461 briefTitle: Co-developing a Novel Intervention to Promote Wellbeing of Family Caregivers of Individuals With Spinal Cord Injury overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-05 date: 2025-11 date: 2024-04-15 date: 2024-04-23 name: University of British Columbia class: OTHER name: The Craig H. Neilsen Foundation briefSummary: Family caregivers of individuals with spinal cord injury (SCI) provide the majority of care and are at high risk of experiencing caregiver burden, which not only impacts caregivers' own wellbeing, but also their ability to respond to patients' needs. Health education using online approaches (eHealth) has the potential to improve quality of care, enhance communication between health care users and providers, reduce costs and increase access to existing knowledge and education for family caregivers. Here, the investigators propose a research study to assess the quality of the eHealth program. The findings of this study will lead to the refinement of the eHealth program. conditions: Spinal Cord Injuries conditions: Caregiver Burden studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: COMPANION eHealth Program measure: Family caregivers' subjective burden as assessed by the Zarit Burden Interview measure: Participants' objective burden as assessed by the Dutch Objective Burden Inventory measure: Participants' distress as assessed by the Depression, Anxiety and Stress Scale measure: Participants' relationship quality satisfaction as assessed by the Dyadic Adjustment Scale measure: Participants' health-related quality of life as assessed by the Veterans RAND 12-item Health Survey measure: Caregiver competence as assessed by the Caregiving Competence Scale measure: Participants' opinion regarding the usability of the implementation as assessed by the System Usability Scale measure: Participants' health care use as assessed by a bespoke questionnaire measure: Participants' experience using the implementation as assessed by a qualitative interview measure: A composite measure of recruitment rate, consent rate, retention rate, perceived benefit, and assessor masking will be evaluated as "successful" or "revise" according to expectations measure: A composite measure of treatment adherence, participant and evaluator burden during data collection, and expert burden will be evaluated as "successful" or "revise" according to expectations measure: A composite measure of internet stability, participant processing time, and treatment administration issues will be evaluated as "successful" or "revise" according to expectations measure: A measure of dose level of training time sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06364800 id: GDT-001-07-02 briefTitle: Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody overallStatus: NOT_YET_RECRUITING date: 2024-04-26 date: 2026-04-26 date: 2026-09-26 date: 2024-04-15 date: 2024-04-15 name: Beijing 302 Hospital class: OTHER name: Chinese Academy of Medical Sciences name: Beijing GD Initiative Cell Therapy Technology Co., Ltd. briefSummary: The purpose of this study is to evaluate the safety and efficacy of allogeneic γδ T cells combined with targeted therapy and PD-1 monoclonal antibody in patients with hepatocellular carcinoma resistant to PD-1 monoclonal antibody.
Hepatocellular Carcinoma conditions: Hepatocellular Carcinoma studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 18 type: ESTIMATED name: γδ T cells name: PD-1 monoclonal antibody name: targeted drugs measure: Safety evaluation: Incidence of Adverse events (AEs) measure: Safety evaluation: Dose limited toxicity (DLTs) measure: Efficacy evaluation: Objective Response Rate(ORR) measure: Efficacy evaluation: Duration of Response(DOR) measure: Efficacy evaluation: Progress Free Survival(PFS) measure: Efficacy evaluation: Overall Survival (OS) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06364787 id: GDT-001-07-01 briefTitle: Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma overallStatus: NOT_YET_RECRUITING date: 2024-04-26 date: 2026-04-26 date: 2026-09-26 date: 2024-04-15 date: 2024-04-15 name: Beijing 302 Hospital class: OTHER name: Chinese Academy of Medical Sciences name: Beijing GD Initiative Cell Therapy Technology Co., Ltd. briefSummary: The purpose of this study is to evaluate the safety and efficacy of allogeneic γδ T cells combined with targeted therapy and PD-1 monoclonal antibody in first-line treatment of patients with hepatocellular carcinoma. conditions: Hepatocellular Carcinoma studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 18 type: ESTIMATED name: γδ T cells name: Targeted drugs name: PD-1 monoclonal antibody measure: Safety evaluation: Incidence of Adverse events (AEs) measure: Safety evaluation: Dose limited toxicity (DLTs) measure: Safety evaluation: Maximum-tolerated dose (MTD) measure: Efficacy evaluation: Objective Response Rate(ORR) measure: Efficacy evaluation: Duration of Response(DOR) measure: Efficacy evaluation: Progress Free Survival(PFS) measure: Efficacy evaluation: Overall Survival (OS) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06364774 id: 22-020309 briefTitle: ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2027-12-31 date: 2027-12-31 date: 2024-04-15 date: 2024-04-15 name: Children's Hospital of Philadelphia class: OTHER briefSummary: The main goal of this study is to find out if the blood disorder called transfusion-dependent beta thalassemia can be safely treated by modifying blood stem cells. This is done by collecting blood stem cells from the subject, modifying those cells, adding a healthy beta globin gene, and then giving them back to the subject. It is hoped that these modified cells will decrease the need for blood transfusions. The gene modified blood stem cells are called CHOP-ALS20 ("study drug"). This experimental gene therapy has not been tried on human beings before and is not FDA approved. conditions: Beta-Thalassemia studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Single arm pilot, phase I/II study of 12 subjects. primaryPurpose: TREATMENT masking: NONE count: 12 type: ESTIMATED name: ALS20 measure: Neutrophil Engraftment measure: Platelet Engraftment measure: Overall Survival at 2 years measure: Incidence of transplant related mortality measure: Incidence of Graft Versus Host Disease measure: Incidence of Vector-Derived Replication Competent Lentivirus measure: Insertional Oncogenesis measure: Clonal Predominance measure: maintain total hemoglobin level of 9.0 g/dL or higher sex: ALL minimumAge: 18 Years maximumAge: 35 Years stdAges: ADULT facility: Children's Hospital of Philadelphia city: Philadelphia state: Pennsylvania zip: 19104 country: United States name: Janet Kwiatkowski, MD role: CONTACT phone: 215-590-5286 email: kwiatkowski@chop.edu name: Jaladhikumar Patel role: CONTACT phone: 267-426-5602 email: patelj23@chop.edu name: Janet Kwiatkowski, MD role: PRINCIPAL_INVESTIGATOR lat: 39.95233 lon: -75.16379 hasResults: False
nctId: NCT06364761 id: 24103_BIL_EDOF briefTitle: Assesment of Intermediate Vision After BIL Cataract Surgery overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-12 date: 2024-12 date: 2024-04-15 date: 2024-04-15 name: Universitair Ziekenhuis Brussel class: OTHER briefSummary: The goal of this observational study is to learn about the intermediate and near vision in patiënts who underwent cataract surgery with a specific technique, called "bag in the lens".
Researchers will compare these values to the same values from the standard population who underwent the classic lens in the bag cataract surgery with a monofocal intraocular lens . conditions: Cataract studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: CROSS_SECTIONAL count: 38 type: ESTIMATED name: Bag in the lens cataract surgery measure: Intermediate vision measure: Near vision sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06364748 id: 002-2024-Shalowitz briefTitle: Expanding Access to Care Through Telemedical Support for Vital Sign Monitoring in High-risk Patients With Cancer overallStatus: RECRUITING date: 2024-03-11 date: 2025-03 date: 2025-09 date: 2024-04-15 date: 2024-04-15 name: West Michigan Cancer Center class: OTHER name: Veta Health briefSummary: A randomized trial of remote blood pressure monitoring, compared to usual care, in patients receiving bevacizumab to determine whether remote blood pressure monitoring improves the collection of blood pressure data, identification and management of clinically significant hypertension, and patient satisfaction. conditions: Hypertension studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 72 type: ESTIMATED name: Cellular enabled blood pressure cuff name: Standard of Care Cuff measure: To determine whether remote blood pressure monitoring improves adherence to recommendations for daily systolic and diastolic blood pressure monitoring compared to usual care measure: Improvement of early identification of bevacizumab-induced hypertension with usual care blood pressure monitoring measure: Improvement of early identification of bevacizumab-induced hypertension with remote blood pressure monitoring measure: Patient satisfaction with usual care blood pressure monitoring measure: Patient satisfaction with remote blood pressure monitoring sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: West Michigan Cancer Center status: RECRUITING city: Kalamazoo state: Michigan zip: 49007 country: United States name: Wendi Mitchell role: CONTACT phone: 269-373-7443 email: wmitchell@wmcc.org name: Kathleen Allen role: CONTACT phone: 269-373-7452 email: kallen@wmcc.org lat: 42.29171 lon: -85.58723 hasResults: False
nctId: NCT06364735 id: Entità e variabili briefTitle: Entities and Variables Related to Catch-up Growth overallStatus: RECRUITING date: 2024-05-01 date: 2024-11-01 date: 2024-12-01 date: 2024-04-15 date: 2024-04-29 name: ASST Fatebenefratelli Sacco class: OTHER briefSummary: A retrospective monocentric observational no-profit study with the aim of evaluating the entity and potential variables influencing the catch-up growth of childhood gluten-free diet patients with celiac disease during a 10-year follow-up. The only extrapolation of the data collected in anonymized form from the medical records of patients who match the necessary study criteria will be planned in order to achieve this aim. A 900-patient sample size will be planned. conditions: Celiac Disease in Children studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: RETROSPECTIVE count: 900 type: ESTIMATED measure: Measure the catch-up growth degree. measure: Calculate the degree of catch-up growth measure: Exploratory objectives 1 measure: Exploratory objectives 2 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: ASST Fatebenefratelli Sacco status: RECRUITING city: Milan zip: 2015 country: Italy name: Elena MD Groppali role: CONTACT email: elena.groppali@asst-fbf-sacco.it name: Elena MD Groppali role: CONTACT name: Elena MD Groppali role: PRINCIPAL_INVESTIGATOR lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06364722 id: ZYS2024-02 briefTitle: Effect of Acupuncture on the Microbiota-gut-brain Axis in Crohn's Disease overallStatus: COMPLETED date: 2015-05-01 date: 2023-12-31 date: 2024-03-28 date: 2024-04-15 date: 2024-04-15 name: Shanghai Institute of Acupuncture, Moxibustion and Meridian class: OTHER name: Fudan University briefSummary: Multidisciplinary techniques such as multimodal neuroimaging, microbiology, and bioinformatics were applied to study the differences in correlation characteristics between gut microbes, functional brain networks, and peripheral inflammation among patients with active Crohn's disease (CD), CD in remission, and healthy subjects. conditions: Crohn Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: Subjects, efficacy assessors and statisticians were blinded. whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 64 type: ACTUAL name: Acupuncture treatment name: Sham acupuncture measure: Effect of Acupuncture on Crohn's Disease Activity Index (CDAI) measure: Effects of Acupuncture on Anxiety and Depression measure: Effects of Acupuncture on Quality of Life measure: Effect of acupuncture on intestinal inflammation measure: Effects of acupuncture on gut microbiota measure: Effects of acupuncture on the functional activity of brain networks measure: Effects of acupuncture on intestinal inflammation measure: Effect of Acupuncture on Brain Imaging-Gut Microbiological Correlations measure: Safety evaluation (number of participants with abnormal reactions to acupuncture and moxibustion treatment) measure: Safety evaluation (number of participants with abnormal routine blood tests) measure: Safety evaluation (number of participants with abnormal Liver function tests) measure: Safety evaluation (number of participants with abnormal Renal function tests) sex: ALL minimumAge: 16 Years maximumAge: 75 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06364709 id: 4526 id: R01DC015516 type: NIH link: https://reporter.nih.gov/quickSearch/R01DC015516 briefTitle: Criterion-learning Based Naming Treatment in Aphasia overallStatus: NOT_YET_RECRUITING date: 2024-05-15 date: 2028-08 date: 2028-08 date: 2024-04-15 date: 2024-04-15 name: Albert Einstein Healthcare Network class: OTHER name: Thomas Jefferson University name: National Institute on Deafness and Other Communication Disorders (NIDCD) briefSummary: Aphasia is a disorder of spoken and written language, most commonly following a stroke. It is estimated that between 2.5 and 4 million Americans are living with aphasia today. A common problem in aphasia involves difficulty retrieving known words in the course of language production and comprehension. The overarching goal of this project is to develop and test early efficacy, efficiency, and the tolerability of a lexical treatment for aphasia in multiple-session regimens that are comprised of retrieval practice, distributed practice, and training dedicated to the elicitation of correct retrievals. The aim of this work is to add to and refine the evidence base for the implementation and optimization of these elements in the treatment of production and comprehension deficits in aphasia, and make important steps towards an ultimate goal of self-administered lexical treatment grounded in retrieval practice principles (RPP) to supplement traditional speech-language therapy that is appropriate for People with Aphasia (PWA) from a broad level of severity of lexical processing deficit in naming and/or comprehension. This project cumulatively builds on prior work to develop a theory of learning for lexical processing impairment in aphasia that aims to ultimately explain why and for whom familiar lexical treatments work, and how to maximize the benefits they confer. conditions: Aphasia studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 90 type: ESTIMATED name: Criterion-learning practice measure: Trained naming items (Experiment 1) measure: Trained naming items (Experiment 2) measure: Trained naming items (Experiment 3) measure: Trained comprehension items (Experiment 4) measure: Trained naming items (Experiment 1) measure: Trained naming items (Experiment 2) measure: Untrained naming items (Experiment 2) measure: Trained naming items (Experiment 3) measure: Trained naming items (Experiment 4) measure: Trained comprehension items (Experiment 4) measure: Untrained comprehension items (Experiment 4) measure: Treatment compliance (Experiment 2) measure: Connected speech output performance sex: ALL minimumAge: 18 Years maximumAge: 89 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06364696 id: 4396-CL-0101 briefTitle: A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors overallStatus: RECRUITING date: 2024-04-16 date: 2027-04-30 date: 2027-04-30 date: 2024-04-15 date: 2024-04-29 name: Astellas Pharma Inc class: INDUSTRY briefSummary: Genes contain genetic code which tell the body which proteins to make. Some types of cancer are caused by changes, or mutations, in a gene called KRAS. Researchers are looking for ways to stop the actions of abnormal proteins made from the mutated KRAS gene. The so-called G12D mutation in the KRAS gene is common in people with some solid tumors.
Part 1 is called Dose Escalation. Different small groups of people will receive lower to higher doses of ASP4396. For each dose, all medical problems will be recorded. The first group will receive the lowest dose of ASP4396. A medical expert panel will check the results and decide if the next group can receive a higher dose of ASP4396. The panel will do this until all groups have taken ASP4396 or until suitable doses have been selected for Part 2.
After treatment has finished, people in the study will be followed up for up to 45 weeks. conditions: Solid Tumor studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 175 type: ESTIMATED name: ASP4396 measure: Incidence of Dose Limiting Toxicities (DLTs) for ASP4369 measure: Number of Participants with Adverse Events (AEs) measure: Number of Participants with Serious Adverse Events (SAEs) measure: Number of Participants with laboratory value abnormalities and/or AEs measure: Number of Participants with electrocardiogram (ECG) abnormalities and/or AEs measure: Number of Participants with vital sign abnormalities and/or AEs measure: Number of Participants with physical exam abnormalities and/or AEs measure: Number of Participants with Eastern Cooperative Oncology Group (ECOG) performance status score measure: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 measure: Duration of Response (DOR) per RECIST v 1.1 measure: Disease Control Rate (DCR) per RECIST v 1.1 measure: Progression Free Survival (PFS) per RECIST v1.1 measure: Overall Survival (OS) measure: Pharmacokinetics (PK) of ASP4396 in plasma: area under the concentration-time curve from the time of dosing to 24 hours after dosing (AUC24h) measure: PK of ASP4396 metabolite in plasma: AUC24h measure: PK of ASP4396 in plasma: AUC168h measure: PK of ASP4396 metabolite in plasma: AUC168h measure: PK of ASP4396 in plasma: Maximum Concentration (Cmax) measure: PK of ASP4396 metabolite in plasma: Cmax measure: PK of ASP4396 in plasma: concentration immediately prior to dosing at multiple dosing (Ctrough) measure: PK of ASP4396 metabolite in plasma: Ctrough measure: PK of ASP4396 in plasma: Time of maximum concentration (tmax) measure: PK of ASP4396 metabolite in plasma: tmax measure: Change from baseline of Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D amino acid substitution (G12D) tumor samples sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: START Midwest status: RECRUITING city: Grand Rapids state: Michigan zip: 49546 country: United States lat: 42.96336 lon: -85.66809 facility: NEXT Oncology Dallas status: RECRUITING city: Irving state: Texas zip: 75039 country: United States lat: 32.81402 lon: -96.94889 facility: START Mountain Region status: RECRUITING city: West Valley City state: Utah zip: 84119 country: United States lat: 40.69161 lon: -112.00105 facility: NEXT Oncology Virginia status: RECRUITING city: Fairfax state: Virginia zip: 22031 country: United States lat: 38.84622 lon: -77.30637 hasResults: False
nctId: NCT06364683 id: AIBU-HSF-SDEMIR-04 briefTitle: Coronary Artery Disease and Exercise Adherence overallStatus: NOT_YET_RECRUITING date: 2024-05-13 date: 2024-11-13 date: 2025-05-13 date: 2024-04-15 date: 2024-04-15 name: Abant Izzet Baysal University class: OTHER briefSummary: This study aims to determine the factors affecting exercise adherence in patients with coronary artery disease (CAD). For this purpose, the following measurement tools will be used respectively: (1) "Patient Information Form" including sociodemographic characteristics of the patients and medical information related to the disease, (2) the Exercise Adherence Rating Scale (EARS), (3) Exercise Self-Efficacy Scale (ESE) and, (4) Turkish-Health Literacy Survey Europe-Q12 (HLS-EU-19-12Q-TR). Statistical analyses will be carried out by descriptive statistics (number, percentage, mean, standard deviation, etc.), correlation analysis and regression analysis. conditions: Adherence, Treatment conditions: Coronary Artery Disease studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 200 type: ESTIMATED name: Survey study measure: exercise adherence measure: predictors for exercise adherence sex: ALL minimumAge: 18 Years maximumAge: 74 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06364670 id: ZSLL-KY-2023-011-01 briefTitle: Application of Machine Learning Based on fNIRS in Predicting Acupuncture's Efficacy in Treating Tinnitus overallStatus: RECRUITING date: 2024-05 date: 2026-08-31 date: 2026-12-31 date: 2024-04-15 date: 2024-04-15 name: The Third Affiliated hospital of Zhejiang Chinese Medical University class: OTHER briefSummary: This trial aims to use machine learning to analyze fNIRS imaging data of specific brain regions of tinnitus patients, thereby constructing a predictive model of the clinical efficacy of acupuncture for SNT. conditions: Tinnitus studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 500 type: ESTIMATED name: acupuncture measure: Change in resting-state functional connectivity (RSFC) measure: Change in hemoglobin signals measure: Change in Tinnitus Severity Grading measure: Change in Tinnitus Handicap Inventory score measure: Change in average pure-tone threshold sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: the Third Affiliated Hospital of Zhejiang Chinese Medical University status: RECRUITING city: Hangzhou state: Zhejiang zip: 310000 country: China name: Hantong Hu, M.D role: CONTACT phone: 18667103032 phoneExt: 86 email: 413351308@qq.com name: Xiaohan Huang, M.M role: CONTACT phone: 18334334738 phoneExt: 86 email: 1215360683@qq.com name: Hantong Hu, M.D role: PRINCIPAL_INVESTIGATOR lat: 30.29365 lon: 120.16142 hasResults: False
nctId: NCT06364657 id: IRB00439625 briefTitle: Differences in Corneal Structure and Function in Patients With Sjogrens vs. Non-Sjogrens Dry Eye acronym: IIR overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2025-07-31 date: 2027-07-31 date: 2024-04-15 date: 2024-04-15 name: Johns Hopkins University class: OTHER briefSummary: In this study the investigators plan to enroll three groups of patients: non-Sjogren's dry eye, Sjogren's dry eye and controls. The study has the following primary goals: